ThromboGenics jolted with safety questions on eve of FDA panel review

By John Carroll The FDA managed to rattle ThromboGenics‘ investors yesterday with a warning on the adverse events associated with its eye drug ocriplasmin. With an expert panel ...

FDA Seeks Meeting With Sanofi Executives After Warning on Plants

By Albertina Torsoli Inspectors found “significant objectionable conditions” at Sanofi (SAN) vaccine plants in Canadaand France, the U.S. Food and Drug Administration said. Regulators ...

Forest gets FDA nod as tussle with Icahn heats up

New lung drug pegged for $250M by 2015, but Lexapro gap yawns much wider By Tracy Staton Forest Laboratories ($FRX) has a new weapon in its Carl Icahn-fighting arsenal. The FDA approved ...
Page 129 of 129« First...102030...125126127128129
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS